Clinical Usefulness of Serum @entity2355 for Detecting Chronic Aspiration in XXXX with Severe Motor and @entity717 .

@entity1 @entity1851 @entity1030 @entity880 @entity1282 @entity2355 @entity401 @entity717 @entity1173
OBJECTIVE: To determine whether the serum level of @entity2355 ( @entity2355 ), a circulating high-molecular weight glycoprotein and a diagnostic biomarker of @entity401 , is a clinically useful biomarker for detecting chronic @entity1173 in @entity1 with severe motor and @entity717 (SMIDS). STUDY DESIGN: @entity1 with SMIDS undergoing videofluorography for assessment of @entity1282 were prospectively evaluated. Based on the videofluorography results, the @entity1 were classified into @entity1173 and non- @entity1173 groups. Age, sex, white blood cell count, and serum levels of @entity1851 , @entity880 dehydrogenase, albumin, and @entity2355 were compared between the 2 groups. Binary logistic regression was performed to identify factors independently associated with the presence of @entity1173 . RESULTS: A total of 66 @entity1 participated in this study, 37 who were classified as the @entity1173 group and 29 as the non- @entity1173 group. The serum @entity2355 level in the @entity1173 group was significantly higher than that in the non- @entity1173 group (median, 344 U/mL vs 207 U/mL, P  <  .01). Logistic regression modeling showed that the number of prescribed antiepileptic drugs (OR, 1.978; 95% CI, 1.217, 3.214; P  <  .01) and serum @entity2355 level (OR, 1.012; 95% CI, 1.005, 1.019; P  <  .01) were independent predictors of @entity1173 . CONCLUSIONS: The study demonstrated that the @entity2355 level is significantly higher in @entity1 with SMIDS who aspirate than in those who do not. @entity2355 shows promise as a biomarker for @entity1030 due to @entity1173 in these @entity1 .
